Author’s response to reviews

Title: Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study

Authors:
Zongbi Yi (yizongbi@163.com)
Fei Ma (drmafei@126.com)
Binliang Liu (liubinliang_onco@163.com)
Xiuwen Guan (guanxiuwen@foxmail.com)
Lixi Li (1054983057@qq.com)
Chunxiao Li (campuscx@163.com)
Haili Qian (qianhaili001@163.com)
Binghe Xu (bhxu@hotmail.com)

Version: 1 Date: 26 Mar 2018

Author’s response to reviews:

Dear Editor in Chief,

Thank you for your comments on our article. According to your suggestions, we have made extensive revisions to our previous draft. The detailed point-by-point responses are listed below.

Answer: Thanks for your suggestions. We have made revisions accordingly.

2 - Please remove the patient identifiers from the supplementary file and replace them with anonymous identifiers that do not link to patients. This will enable anonymity to be maintained.
Answer: Thanks for your suggestions. We have made revisions accordingly.

3 - Please include a Declarations heading.
Answer: Thanks for your suggestions. We have made revisions accordingly.
4 - In the Funding section of the Declarations please indicate the role of the funding body in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript. If no specific funding was received for this study, please clearly indicate this in the Funding section. Answer: Thanks for your suggestions. We have made revisions accordingly.

5 - Please revise your current Availability of Data and Materials statement to reflect accurately one of the formats indicated in our submission guidelines: https://www.biomedcentral.com/getpublished/editorial-policies#availability+of+data+and+materials Answer: Thanks for your suggestions. We have made revisions accordingly.

6 - For all research involving human subjects, informed consent to participate in the study should be obtained from participants (or their parent or guardian in the case of children under 16) and a statement to this effect should appear in the ‘Ethics approval and consent to participate’ section of the Declarations including whether the consent was written. When reporting on such studies, individual patient data should not be made available unless consent for publication has also been obtained. If the need for informed consent has been waived by an IRB or is deemed unnecessary according to national regulations, please clearly state this with details, including the name of the Board or a reference to the relevant legislation in the ‘Ethics approval and consent to participate’ section of the Declarations. Answer: Thanks for your suggestions. We have made revisions accordingly.

7 - Please provide the reference number(s) for your ethical approval(s). Answer: Thanks for your suggestions. We have made revisions accordingly.